NGEN NervGen Pharma Corp.
NervGen Pharma Corp. (NGEN) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.09 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.0% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About NervGen Pharma Corp.
Nanogen, Inc. integrates advanced microelectronics and molecular biology into a core technology platform with broad and diverse commercial applications in the fields of genomics and biomedical research, medical diagnostics, drug discovery, forensics, agriculture, environmental testing and potentially the electronics and telecommunications industries.
Sector
Healthcare
Industry
Biotechnology